First GLP-1 analog liraglutide: the result of clinical trails on efficacy
https://doi.org/10.14341/2072-0351-5815
Abstract
This review analytically considers the results of clinical trials on efficacy and safety and clinical perspectives of GLP-1 analog liraglutide
About the Authors
Alexander Sergeevich Ametov
Russian Medical Academy of Postgraduate Education, Moscow
Lyudmila Leonidovna Kamynina
Russian Medical Academy of Postgraduate Education, Moscow
References
1. Дедов И.И., Шестакова М.В. Виктоза®(ЛИРАГЛУТИД): первый аналог человеческого ГПП-1 в лечении сахарного диабета 2-го типа Практическое руководство для врачей. - М.: Дипак, 2010. - 48 с.
2. Шестакова М.В. Лираглутид - возможности комплексного терапевтического подхода в терапии сахарного диабета 2 типа // Сахар- ный диабет. - 2010. - Спецвыпуск. - С. 3-6.
3. Галстян Г.Р. Клиническое аспекты использования первого аналога человеческого глюкагоноподобного пептида-1 длительного дей- ствия - лираглутида при сахарном диабете 2 типа // Сахарный диа- бет. - 2010. - Спецвыпуск. - С. 7-10.
4. Анциферов М.Б., Дорофеева Л.Г. Перспективы применения первого аналога человеческого глюкагоноподобного пептида-1, лираглу- тида, в терапии пациентов с сахарным диабетом типа 2 // Фарма- тека. - 2009. - № 3. - С. 7-23.
5. Аметов А.С., Камынина Л.Л. Роль и место первого человеческого аналога ГПП-1 лираглутида в практике эндокринолога // Сахар- ный диабет 2 типа: проблемы и решения. - М.: ГЕОТАР, 2011. - С. 380-404.
6. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., Bode B.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial // Lancet. - 2009. -№ 373. - P. 438-439.
7. Garber A., Henry R., Ratner R., Hale P., Chang C.T., Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reduction in A1C, FGP and weight compared with glimepiride in type 2 diabetes: LEAD-3 Mono 2-years results // 69th ADA Scientific Sessions Abstract Book. - 2009. - Р. 162-OR.
8. Gallwitz B., Vaag A., Falahati A., Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time // Int. J. Clin. Pract. -2010. - № 64(2). - P. 267-276.
9. Nauck M., Frid A., Hermansen K., Shah N.S., Tankova T., Mitha I.H., Zdravkovic M., Düring M., Matthews D.R.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study // Diabetes Care. - 2009. - № 32(1). - P. 84-90.
10. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) // Diabet Med. - 2009. - № 26(3). - P. 268-278.
11. Zinman B., Gerich J., Buse J.B., Lewin A., Schwartz S., Raskin P., Hale P.M., Zdravkovic M., Blonde L.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) // Diabetes Care. - 2009. - № 32 (7). - P. 1224-1230.
12. Russell-Jones D., Vaag A., Schmitz O., Sethi B.K., Lalic N., Antic S., Zdravkovic M., Ravn G.M., Simó R.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia // 2009. - № 52(10). - P. 2046-2055.
13. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., Zychma M., Blonde L.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) // Lancet. 2009. - № 374 (9683). - P. 39-47.
14. Matthews D., Vilsboll T., Courreges J.-P., Zychma M., Falahati A., Seino Y., Bode B. Liraglutide Improves -Cell Function as Assessed by HOMA-B and Proinsulin:Insulin Ratio: Meta-Analysis of 6 Clinical Trials // 70th ADA Scientific Sessions. - 2010. - 1513.
15. Blonde L., Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies // Diabetes Obes. Metab. - 2009. - Suppl 3. - P. 26-34.
16. McGill J.B. Liraglutide: effects beyond glycaemic control in diabetes treatment // Int. J. Clin. Pract. Suppl. - 2010. - № 64 (167). - P. 28-34.
17. Davies M.J., Kela R., Khunti K. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes // Diabetes Obes. Metab. - 2011. - № 13 (3). - P.207-220.
18. Yang W., Chen L., Ji Q., Liu X., Ma J., Tandon N., Bhattacharyya A., Kumar A., Kim K.W., Yoon K.H., Bech O.M., Zychma M. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial // Diabetes Obes. Metab. - 2011. - № 13 (1). - P. 81-88.
19. Vilsboll T., Brock B., Perrild H., Levin K., Lervang H.H., Kølendorf K., Krarup T., Schmitz O., Zdravkovic M., Le-Thi T., Madsbad S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus // Diabet Med. - 2008. - № 25 (2). - P. 152-156. 20. Courrèges J.P., Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T.,
20. Schmitz O., Verhoeven R., Bugáñová I., Madsbad S. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes // Diabet Med. - 2008. - № 25 (9). - P. 1129-1131.
21. Hattori Y., Jojima T., Tomizawa A., Satoh H., Hattori S., Kasai K., Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells // Diabetologia. - 2010. - № 53 (7). - P. 2256-2263.
22. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., Baggio L.L., Henkelman R.M., Husain M., Drucker D.J. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice // Diabetes. - 2009. - № 58 (4). - P. 975-983.
Review
For citations:
Ametov A.S., Kamynina L.L. First GLP-1 analog liraglutide: the result of clinical trails on efficacy. Diabetes mellitus. 2011;14(4):39-45. (In Russ.) https://doi.org/10.14341/2072-0351-5815
Views:
2045
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
